ReviewBiomolecules2016
The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation.
Review in Biomolecules, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Review
- DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.JCO precision oncology · 2024Article
- Epigenetic reprogramming in gastrointestinal cancer: biology and translational perspectives.MedComm · 2024Review
- Recent advances in the role of endogenous hydrogen sulphide in cancer cells.Cell proliferation · 2023Review
- Ferroptosis open a new door for colorectal cancer treatment.Frontiers in oncology · 2023Review
- Recent advances in understanding DNA methylation of prostate cancer.Frontiers in oncology · 2023Review
- Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma.Frontiers in endocrinology · 2022Article
- Targeted Assessment ofClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Detecting Chromosome Instability in Cancer: Approaches to Resolve Cell-to-Cell Heterogeneity.Cancers · 2019Review
- Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas.Cancer informatics · 2019Article
- Epigenetics in ovarian cancer.Seminars in cancer biology · 2018Review
- Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.Neuro-oncology · 2018Review
- Overview on Clinical Relevance of Intra-Tumor Heterogeneity.Frontiers in medicine · 2018Review
- MicroRNA in Glioblastoma: An Overview.International journal of genomics · 2017Review
- Gliomas display distinct sex-based differential methylation patterns based on molecular subtype.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Epigenetic dysregulation is recognized as a hallmark of cancer. In the last 16 years, a CpG island methylator phenotype (CIMP) has been documented in tumors originating from different tissues. However, a looming question in the field is whether or not CIMP is a pan-cancer phenomenon or a tissue-specific event. Here, we give a synopsis of the history of CIMP and describe the pattern of DNA methylation that defines the CIMP phenotype in different cancer types. We highlight new conceptual approaches of classifying tumors based on CIMP in a cancer type-agnostic way that reveal the presence of distinct CIMP tumors in a multitude of The Cancer Genome Atlas (TCGA) datasets, suggesting that this phenotype may transcend tissue-type specificity. Lastly, we show evidence supporting the clinical relevance of CIMP-positive tumors and suggest that a common CIMP etiology may define new mechanistic targets in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.